We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY
Read MoreHide Full Article
Microbot Medical Inc. (MBOT - Free Report) recently signed a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System. The company has received the Institutional Review Board’s approval to begin the trial at this site.
The Baptist Hospital of Miami includes the Miami Cardiac & Vascular Institute and the Miami Cancer Institute.
The latest trial agreement should boost MBOT’s confidence and help it advance with the use of surgical robotics in endovascular interventional procedures.
About LIBERTY
LIBERTY is a single-use endovascular surgical robotic system designed to streamline endovascular procedures. It eliminates the need for large, cumbersome, and expensive capital equipment while reducing radiation exposure and physician strain.
More on the News
The Baptist Hospital is the second site that will participate in the clinical trial for Microbot’s LIBERTY as part of its Investigational Device Exemption (IDE). The company recently announced the Brigham and Women's Hospital as another participating site.
Image Source: Zacks Investment Research
Market Prospect
Per a Future Market Insights report, the robotic-assisted endovascular systems market size is expected to surpass $214.7 million by 2033, at a CAGR of 8.6% during the period. The market growth is influenced by the increasing need for cutting-edge treatment alternatives due to the rise of cardiovascular illnesses, peripheral artery diseases, and other vascular disorders. Also, the growing demand for innovative, minimally invasive surgical procedures that reduce patient trauma and recovery time drives the market’s growth.
Looking at the market potential, Microbot’s IDE for its LIBERTY system is perfectly timed.
Other Notable Developments
In June 2024, Microbot received the Food and Drug Administration’s (FDA) approval to proceed with its pivotal human clinical trial as part of its IDE application for its LIBERTY Endovascular Robotic Surgical System.
Earlier this year, Microbot announced the completion of its collaboration with Corewell Health. The collaboration demonstrated the LIBERTY System's technical capabilities and outlined potential applications in a range of endovascular interventions.
Price Performance
Year to date, shares of MBOT have lost 36% against the industry’s 3.4% growth.
Zacks Rank and Key Picks
Microbot currently carries a Zacks Rank #4 (Sell).
The Hims & Hers Heath stock has surged 130.5% in the past year. Estimates for the company’s 2024 earnings have moved north by 5.6% to 19 cents per share in the past 30 days.
HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for The Joint’s 2024 earnings per share (EPS) have remained constant at 21 cents in the past 30 days. Shares of JYNT have surged 38.8% year to date against the industry’s 5.3% decline.
In the last reported quarter, JYNT delivered an earnings surprise of 300%. It has a trailing four-quarter average earnings surprise of 18.75%.
Estimates for Medpace’s 2024 EPS have remained unchanged at $11.29 in the past 30 days. Shares of the company have soared 70.1% in the past year compared with the industry’s 4.6% growth.
MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY
Microbot Medical Inc. (MBOT - Free Report) recently signed a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System. The company has received the Institutional Review Board’s approval to begin the trial at this site.
The Baptist Hospital of Miami includes the Miami Cardiac & Vascular Institute and the Miami Cancer Institute.
The latest trial agreement should boost MBOT’s confidence and help it advance with the use of surgical robotics in endovascular interventional procedures.
About LIBERTY
LIBERTY is a single-use endovascular surgical robotic system designed to streamline endovascular procedures. It eliminates the need for large, cumbersome, and expensive capital equipment while reducing radiation exposure and physician strain.
More on the News
The Baptist Hospital is the second site that will participate in the clinical trial for Microbot’s LIBERTY as part of its Investigational Device Exemption (IDE). The company recently announced the Brigham and Women's Hospital as another participating site.
Image Source: Zacks Investment Research
Market Prospect
Per a Future Market Insights report, the robotic-assisted endovascular systems market size is expected to surpass $214.7 million by 2033, at a CAGR of 8.6% during the period. The market growth is influenced by the increasing need for cutting-edge treatment alternatives due to the rise of cardiovascular illnesses, peripheral artery diseases, and other vascular disorders. Also, the growing demand for innovative, minimally invasive surgical procedures that reduce patient trauma and recovery time drives the market’s growth.
Looking at the market potential, Microbot’s IDE for its LIBERTY system is perfectly timed.
Other Notable Developments
In June 2024, Microbot received the Food and Drug Administration’s (FDA) approval to proceed with its pivotal human clinical trial as part of its IDE application for its LIBERTY Endovascular Robotic Surgical System.
Earlier this year, Microbot announced the completion of its collaboration with Corewell Health. The collaboration demonstrated the LIBERTY System's technical capabilities and outlined potential applications in a range of endovascular interventions.
Price Performance
Year to date, shares of MBOT have lost 36% against the industry’s 3.4% growth.
Zacks Rank and Key Picks
Microbot currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Hims & Hers Health, Inc. (HIMS - Free Report) , The Joint Corp. (JYNT - Free Report) , and Medpace Holdings (MEDP - Free Report) . While Hims & Hers and The Joint currently sport a Zacks Rank #1 (Strong Buy) each, Medpace Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Hims & Hers Heath stock has surged 130.5% in the past year. Estimates for the company’s 2024 earnings have moved north by 5.6% to 19 cents per share in the past 30 days.
HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for The Joint’s 2024 earnings per share (EPS) have remained constant at 21 cents in the past 30 days. Shares of JYNT have surged 38.8% year to date against the industry’s 5.3% decline.
In the last reported quarter, JYNT delivered an earnings surprise of 300%. It has a trailing four-quarter average earnings surprise of 18.75%.
Estimates for Medpace’s 2024 EPS have remained unchanged at $11.29 in the past 30 days. Shares of the company have soared 70.1% in the past year compared with the industry’s 4.6% growth.
MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.